Biopharma Stocks Outperforming In $471 Billion Market (STAB, GILD, EXEL, MRK, JNJ)

Biopharmaceutical stocks are soaring this year. As a sector, the biopharma industry has grown 38% per year over the past three years. Sector stock revenues have grown cumulatively 10% annually and are seen repeating that performance for the next five years.

Biopharma will be a $471.02 billion market by 2027, according to, growing at a CAGR of 9.1+%. 

Biopharma companies are researching vaccines and treatments for COVID-19, COVID-19 long-haul, pediatric Crohn’s disease plus cancers and Alzheimer’s disease.


This sector of stocks is not only outperforming the market, it also clinically tests the performance of commercially-potential candidate drugs. The goal is to address diseases that range from the pandemic of COVID-19 to cancers and addictive smoking impacting the lungs.

Here are the leading biopharmaceutical stocks you can buy. Starting with STAB a stock making progress on a pilot study protocol with the FDA.


— Statera Biopharma, Inc. (NASDAQ: STAB) submits pilot study protocol of its clinical study of long haul COVID-19. The protocol is for its STAT-205 drug candidate and treatment of long haul post-acute SARS-CoV-2.

“Submitting this study protocol to the FDA is a critical milestone in the development of our COVID-19 program. As the world continues to struggle with the COVID-19 pandemic, post-acute COVID syndrome remains a widespread often debilitating condition that is not well understood,” says Michael K. Handley, president, and CEO of the biopharmaceutical company. “With STAT-205 Statera looks to potentially offer a promising treatment approach to those patients facing the long-lasting burden of the illness.”

“We have taken numerous steps to further the development of our clinical-stage pipeline that has us well-positioned to achieve numerous milestones in 2022,” says Handley.


Investors should put STAB stock on their Watch Lists as biopharmaceutical companies performing clinical-stage research are rising in valuation.

STAT-205 is currently being evaluated in Phase 1 clinical trial in adult patients with mild COVID-19 who are at high risk of disease progression. It is halfway through its patient enrollment. Enrollment is expected to be completed in Q3 with top-line results available in Q4.

STAB is a clinical-stage biopharmaceutical company. It specializes in researching immunotherapies targeting autoimmune neutropenia/anemia emerging viruses. The goal is to develop a proprietary platform designed to rebalance the body’s immune system and remote homeostasis. The Company has clinical programs for Crohn’s disease and deadly pancreatic cancer. 


— Gilead Sciences, Inc. (NASDAQ: GILD) is an American biopharmaceutical stock that specializes in the R&D of anti-viral drugs addressing HIV, hepatitis, and influenza. GILD has developed several commercialized drugs such as Biktarvy and Genvoya for HIV and Veklury® for COVID-19. For its fiscal year ended December 31, its volume rose 10.6% to $27.3 billion.

Last month it declared a 2.8% higher quarterly dividend indicative of its strong balance sheet and ability to pay back shareholders. Earlier this year it received expedited approval from the FDA of its drug Veklury®. It is formulated for the treatment of non-hospitalized patients at risk of progression to severe COVID-19.  

— Alexis, Inc. (NASDAQ: EXEL)is a biopharmaceutical company focused on R&D for cancer cures. It has beaten the consensus estimates of analysts. Volume spiked 67% to $ 451.1 million for the Q4 current completed quarter vs $270 million for the comparable quarter the prior year. 

This is a company focused on oncology and developing treatments for cancers. It has research collaborations and licenses with several notable companies. It is currently working on R&D and commercialization of a novel anti-cancer compound. This in-house license agreement strengthens its pipeline.

— Merck (NYSE: MRK) has grown share EPS by 28% annually, by compound, over the past three years. Over the past 12 months, MRK’s EBIT margins improved by 4% to 37%. This is a US $192 billion company.

This is a successful drug maker. Driving sales have been its products Keytruda, Lynparza and Bridion. They are all formulated to treat lung cancers and other cancers. In MRK’s pipeline is a promising oral antiviral pill.

— Johnson & Johnson (NYSE: JNJ) may be a special buy opportunity after its recent $100 million baby power settlement. Insider investors know that J&J will use a subsidiary, such as LTL Management, as part of its legal strategy to take the financial hit, according to Forbes. That way its core business would not be impacted.

J&J has an extensive late-stage drug pipeline. It has an aggressive pipeline and line extensions and sees the biopharmaceutical industry receiving in 2022 from its performance in 2021. J&J maintains a strong cash position enabling it to grow its biopharma business.  Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at

This article is part of a sponsored investor education program.